AWM
CNST

Accel Wealth Management’s Constellation Pharmaceuticals, Inc. CNST Stock Holding History

Accel Wealth Management’s Portfolio CNST Stock Details CNST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-250
Closed -$6K – 929
2021
Q1 		$6K Sell
250
-1,100
-81% -$33.3K ﹤0.01% 740
2020
Q4 		$39K Buy
+1,350
New +$34K 0.04% 344

Other funds holding CNST

ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CG
Column Group San Francisco, California $101M AUM 290.34% 1-Year Est. Return
PM
Ponoi Management San Francisco, California $73.2M AUM 23.44% 1-Year Est. Return
OPU
Omni Partners US Irvine, California $1.95B AUM
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VI
Versor Investments New York $40.8M AUM 93.59% 1-Year Est. Return
PIM
Ponoi II Management San Francisco, California $38.3M AUM 32.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Accel Wealth Management's CNST Position: Q2 2021 in Review

Accel Wealth Management sold out of Constellation Pharmaceuticals, Inc. (CNST) in Q2 2021, closing a stake of 250 shares — an estimated $6K sold.

Accel Wealth Management first reported a position in CNST in Q4 2020 and held it in 2 quarters. The position peaked at $39K in Q4 2020. 153 funds tracked by Wall St. Rank hold CNST as of Q2 2021.

  • Accel Wealth Management reported no remaining Constellation Pharmaceuticals, Inc. position as of Q2 2021 after selling out during the quarter.
  • Accel Wealth Management sold 250 Constellation Pharmaceuticals, Inc. shares in Q2 2021, an estimated $6K.
  • Accel Wealth Management first reported a position in Constellation Pharmaceuticals, Inc. in Q4 2020 and held it in 2 quarters.
  • Accel Wealth Management's Constellation Pharmaceuticals, Inc. position peaked at $39K in Q4 2020.
  • 153 funds tracked by Wall St. Rank held Constellation Pharmaceuticals, Inc. as of Q2 2021.

Based on Accel Wealth Management's 13F filing for Q2 2021, filed 3 Aug 2021.